Cannabis company Pivot Pharmaceuticals Inc (CSE:PVOT) (OTCQB:PVOTF) (FRA:NPAT) reported on Wednesday that it has signed a Letter of Intent (LOI) with Pharmascience Inc.
Under the terms of the LOI, Pharmascience will conduct analytical testing and collaborate on development and research of new medicinal products containing cannabis or cannabis derivatives and drugs containing cannabis and/or cannabis derivatives.
It will also provide regulatory support necessary to attain Marketing Authorization, and marketing and distribution of finished pharmaceutical dosage forms.
Pharmascience is the fourth largest manufacturer of over-the-counter generic drugs in Canada and is a leading manufacturer and marketer of prescription generic, over-the-counter and behind-the-counter products as well as US FDA approved Canadian-made injectables.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling